At the news
? NEUTRALIMPACT 2/10 SC 13G/A filed Nov 5, 2026 at 13:27 ET
FMR LLC (Fidelity) filed an amended Schedule 13G disclosing a 7.5% beneficial ownership stake in Stoke Therapeutics as of September 30, 2026, up from 5% or greater in the prior filing. The increase from a passive holder is routine and does not signal activist intent.
- FMR LLC reported beneficial ownership of 4,820,462.07 shares of Stoke Therapeutics common stock as of September 30, 2026
- The stake represents 7.5% of shares outstanding
- This is an amendment to a prior Schedule 13G, indicating an increase from the previously reported 5%+ stake
- The filing is made under Rule 13d-1(b), confirming passive investment intent
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access